174 related articles for article (PubMed ID: 25549897)
1. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
Lacivita E; Schepetkin IA; Stama ML; Kirpotina LN; Colabufo NA; Perrone R; Khlebnikov AI; Quinn MT; Leopoldo M
Bioorg Med Chem; 2015 Jul; 23(14):3913-24. PubMed ID: 25549897
[TBL] [Abstract][Full Text] [Related]
2. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
3. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
4. Structural changes of the ligand and of the receptor alters the receptor preference for neutrophil activating peptides starting with a formylmethionyl group.
Forsman H; Winther M; Gabl M; Skovbakke SL; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2015 Jan; 1853(1):192-200. PubMed ID: 25447672
[TBL] [Abstract][Full Text] [Related]
5. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
Stama ML; Ślusarczyk J; Lacivita E; Kirpotina LN; Schepetkin IA; Chamera K; Riganti C; Perrone R; Quinn MT; Basta-Kaim A; Leopoldo M
Eur J Med Chem; 2017 Dec; 141():703-720. PubMed ID: 29102463
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization and inhibitory profile of formyl peptide receptor 2 selective peptides descending from a PIP2-binding domain of gelsolin.
Forsman H; Andréasson E; Karlsson J; Boulay F; Rabiet MJ; Dahlgren C
J Immunol; 2012 Jul; 189(2):629-37. PubMed ID: 22706076
[TBL] [Abstract][Full Text] [Related]
7. The proteolytically stable peptidomimetic Pam-(Lys-βNSpe)6-NH2 selectively inhibits human neutrophil activation via formyl peptide receptor 2.
Skovbakke SL; Heegaard PM; Larsen CJ; Franzyk H; Forsman H; Dahlgren C
Biochem Pharmacol; 2015 Jan; 93(2):182-95. PubMed ID: 25462815
[TBL] [Abstract][Full Text] [Related]
8. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.
Cilibrizzi A; Quinn MT; Kirpotina LN; Schepetkin IA; Holderness J; Ye RD; Rabiet MJ; Biancalani C; Cesari N; Graziano A; Vergelli C; Pieretti S; Dal Piaz V; Giovannoni MP
J Med Chem; 2009 Aug; 52(16):5044-57. PubMed ID: 19639995
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
[TBL] [Abstract][Full Text] [Related]
10. Radiosynthesis and in vivo Evaluation of Carbon-11 (2S)-3-(1H-Indol-3-yl)-2-{[(4-methoxyphenyl)carbamoyl]amino}-N-{[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl}propanamide: An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neuroinflammation.
Lacivita E; Stama ML; Maeda J; Fujinaga M; Hatori A; Zhang MR; Colabufo NA; Perrone R; Higuchi M; Suhara T; Leopoldo M
Chem Biodivers; 2016 Jul; 13(7):875-83. PubMed ID: 27251949
[TBL] [Abstract][Full Text] [Related]
11. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors.
Forsman H; Dahlgren C
Scand J Immunol; 2009 Oct; 70(4):396-402. PubMed ID: 19751275
[TBL] [Abstract][Full Text] [Related]
12. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
Stepniewski TM; Filipek S
Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Quinn MT
Mol Pharmacol; 2007 Apr; 71(4):1061-74. PubMed ID: 17229869
[TBL] [Abstract][Full Text] [Related]
14. Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages.
Marutani T; Nishino K; Miyaji T; Kamada K; Ohura K; Kiso Y; Mukai H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920954
[TBL] [Abstract][Full Text] [Related]
15. Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
Asahina Y; Wurtz NR; Arakawa K; Carson N; Fujii K; Fukuchi K; Garcia R; Hsu MY; Ishiyama J; Ito B; Kick E; Lupisella J; Matsushima S; Ohata K; Ostrowski J; Saito Y; Tsuda K; Villarreal F; Yamada H; Yamaoka T; Wexler R; Gordon D; Kohno Y
J Med Chem; 2020 Sep; 63(17):9003-9019. PubMed ID: 32407089
[TBL] [Abstract][Full Text] [Related]
16. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
Lind S; Sundqvist M; Holmdahl R; Dahlgren C; Forsman H; Olofsson P
Biochem Pharmacol; 2019 Aug; 166():163-173. PubMed ID: 31085160
[TBL] [Abstract][Full Text] [Related]
17. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
[TBL] [Abstract][Full Text] [Related]
19. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
20. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist.
Sogawa Y; Shimizugawa A; Ohyama T; Maeda H; Hirahara K
J Pharmacol Sci; 2009 Nov; 111(3):317-21. PubMed ID: 19926937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
